State Street’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

State Street’s Portfolio GRCL Stock Details GRCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-12,400	Closed	-$47.2K	–	4629
2023 Q2	$47.2K	Buy	12,400 +486	+4%	+$1.36K	﹤0.01%	4432
2023 Q1	$22.2K	Buy	11,914 +1,098	+10%	+$2.29K	﹤0.01%	4674
2022 Q4	$24.9K	Buy	+10,816	New	+$33.1K	﹤0.01%	4698
2021 Q4	–	Sell	-14,420	Closed	-$200K	–	4825
2021 Q3	$200K	Buy	+14,420	New	+$170K	﹤0.01%	4361

Other funds holding GRCL

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

State Street's GRCL Position: Q3 2023 in Review

State Street sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q3 2023, closing a stake of 12,400 shares — an estimated $47.2K sold.

State Street first reported a position in GRCL in Q3 2021 and held it in 4 quarters. The position peaked at $200K in Q3 2021. 45 funds tracked by Wall St. Rank hold GRCL as of Q3 2023.

State Street reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q3 2023 after selling out during the quarter.
State Street sold 12,400 Gracell Biotechnologies Inc. American Depositary Shares shares in Q3 2023, an estimated $47.2K.
State Street first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q3 2021 and held it in 4 quarters.
State Street's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $200K in Q3 2021.
45 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q3 2023.

Based on State Street's 13F filing for Q3 2023, filed 14 Nov 2023.